Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab vs paclitaxel/irinotecan in advanced esophageal squamous cell carcinoma after first-line failure
CTR20170258Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Innovent Biologics. Started Mar 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20170258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170258.